RxDoctor Payments Data

Russ Altman

Internal Medicine · Stanford, CANPI 1497813810

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,289 of the $8,437 with a category attached, or 98.2%. GSK accounts for 92.3% of it on its own, with 2 other manufacturers making up the rest. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,437in general payments, 2019–2025

Across 4 payments — averaging $2109.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$8K
  • Pfizer$500
  • Genentech, Inc.$148
$608,637in research payments, 2019–2025

Across 4 payments — averaging $152,159 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$423K
  • Janssen Research & Development, LLC$186K

What the payments were for

  • Consulting fees$8,28998%
  • Travel & lodging$771%
  • Food & beverage$721%

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK1$7,789
Pfizer1$500
Genentech, Inc.2$148

How this compares

$8,437 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Other internal medicine in Stanford

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →